论文部分内容阅读
目的评价国产吉西他滨(泽菲)加卡铂治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法卡铂AUC4～6(初治6,复治4～5)静脉滴注第1天。泽菲1000mg/m2,第1、8d静脉滴注,3周重复。结果60例,客观有效率45.5%(27/60),初治患者有效率50.0%,复治病人有效率27.8%,主要不良反应为骨髓抑制、消化道反应、静脉炎。结论国产吉西他滨加卡铂的两联化疗在晚期NSCLC中有较好疗效,不良反应可以耐受。
Objective To evaluate the efficacy and adverse reactions of domestic gemcitabine (Zephyr) plus carboplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Carboplatin AUC4 ~ 6 (initial treatment 6, retreatment 4 ~ 5) intravenous drip on the first day. Zefei 1000mg / m2, the first 1,8d intravenous infusion, 3 weeks repeated. The results of 60 cases, the objective efficiency of 45.5% (27/60), the initial treatment of patients with an effective rate of 50.0%, refractory patients effective rate of 27.8%, the main adverse reactions of bone marrow suppression, gastrointestinal reactions, phlebitis. Conclusions The dual chemotherapy with domestic gemcitabine plus carboplatin has better curative effect in advanced NSCLC and the adverse reactions can be tolerated.